Table 2.

Details of the ten children without peak growth hormone concentrations greater than 7 ng/ml after fasting study and glucagon administration.

Patient	1	2	3	4	5	6	7	8	9	10
Age, yrs	7.5	1.2	5.3	1.8	1.4	5.1	0.1	2.6	6.1	0.7
Sex	male	male	female	male	female	female	male	male	female	male
Height, Z-score	−1.2	− 0.81	−2.33	−2.2	−4.1	−0.75	−0.02	−2.47	−3.6	−0.94
Midparental Height, Z-score	−0.43	NA	−0.68	0.24	−0.87	−0.46	NA	NA	−0.48	0.25
MRI Brain and Pituitary	normal	NP	NP	normal	NP	NP	abnormal corpus callosum	NP	ectopic neurohypophysis	normal
Fast Duration, hours	24	15	20	17	10	16	4	13	14	10
Critical Sample
Glucose (mg/dL)	41	45	49	47	43	51	46	53	45	52
Betahydroxybutyrate (mmol/L)	2.9	1.2	2.2	2.9	2.5	4	0.1	2.5	0.8	2.3
Growth Hormone, ng/ml	3.6	1	1.1	2.4	3.5	3.5	0.8	2.4	0.1	3.2
Cortisol, mcg/dL	20.8	14.4	28.9	9.3	14.3	40.7	14.9	16.3	6	20.6
Peak GH after glucagon (ng/mL)	5.4	5.2	5.5	5.1	4.7	5.7	4.3	4.7	0.3	6.6
Peak GH on repeat GH stimulation test (ng/mL)	7.1	4.6		6.5	3.7	8.2	1.9	6.2	0.4	1.5
Thyroid function tests	normal	NP	normal	normal	normal	NP	normal	normal	normal	normal
IGF-I Z-score	−1.4	NP	0.1	−0.9	−3.1	NP	0.7	−1.5	−2.6	−0.7
IGFBP-3 Z-score	−1.6	NP	−0.74	−0.18	−1.6	NP	0.77	−0.73	NP	−2
Diagnosis	GHD*	HI	KH	GHD	GHD	KH	GHD	Resolved focal HI	GHD, AI	GHD

^*Additional clinical data supporting diagnosis of GHD: Height velocity 3 cm/yr, bone age delayed by 2 years (−2.3 SD from mean), improved growth and no further hypoglycemia following GH treatment..

GH = Growth Hormone, GHD = Growth Hormone Deficiency, HI = Diazoxide Responsive Hyperinsulinism, KH = Ketotic Hypoglycemia, AI = Adrenal Insufficiency, NA = Data not available, NP = Test not performed